(CPIX) Cumberland Pharmaceuticals - Overview
Injection, Acetaminophen, Pain, Fever, Constipation
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 91.1% |
| Relative Tail Risk | -18.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 46.36 |
| Character TTM | |
|---|---|
| Beta | 0.890 |
| Beta Downside | 0.500 |
| Drawdowns 3y | |
|---|---|
| Max DD | 71.94% |
| CAGR/Max DD | 0.17 |
Description: CPIX Cumberland Pharmaceuticals January 07, 2026
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is a specialty pharma firm that acquires, develops, and commercializes injectable and oral prescription products for hospital acute-care, gastroenterology, and oncology markets in the U.S. and abroad. The company was founded in 1999 and is headquartered in Nashville, Tennessee.
The current product lineup includes Acetadote (acetaminophen-overdose antidote), Caldolor (pain/fever management), Kristalose (laxative solution), Sancuso (anti-emetic for chemotherapy), Vaprisol (hyponatremia treatment), and Vibativ (antibiotic for hospital-acquired pneumonia and skin infections). Its pipeline features ifetroban, which has completed Phase II trials for Duchenne-related cardiomyopathy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease, and is now in Phase II for systemic sclerosis and idiopathic pulmonary fibrosis.
According to the most recent SEC filing (FY 2023), CPIX generated $68 million in revenue, a 12 % year-over-year increase driven primarily by Vibativ sales, while cash and cash equivalents stood at $45 million, providing roughly 18 months of runway at current burn rates. R&D expense was $9 million, representing about 13 % of revenue, reflecting the company’s focus on advancing the ifetroban program.
Key sector drivers include rising hospital drug spending (projected CAGR ≈ 5 % through 2028) and an expanding inpatient population due to an aging demographic, which together support demand for injectable therapies. However, CPIX’s reliance on a limited product portfolio and the binary outcomes of its Phase II trials introduce material execution risk.
For a deeper dive into CPIX’s valuation metrics and risk profile, consult the ValueRay analysis page.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -3.33m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 12.30 > 1.0 |
| NWC/Revenue: 13.64% < 20% (prev 11.28%; Δ 2.36% < -1%) |
| CFO/TA 0.10 > 3% & CFO 6.83m > Net Income -3.33m |
| Net Debt (-4.96m) to EBITDA (2.68m): -1.85 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.0m) vs 12m ago 6.41% < -2% |
| Gross Margin: 84.49% > 18% (prev 0.83%; Δ 8366 % > 0.5%) |
| Asset Turnover: 57.88% > 50% (prev 47.93%; Δ 9.94% > 0%) |
| Interest Coverage Ratio: -4.57 > 6 (EBITDA TTM 2.68m / Interest Expense TTM 606.3k) |
Altman Z'' -0.27
| A: 0.09 (Total Current Assets 29.9m - Total Current Liabilities 24.3m) / Total Assets 65.9m |
| B: -0.39 (Retained Earnings -25.4m / Total Assets 65.9m) |
| C: -0.04 (EBIT TTM -2.77m / Avg Total Assets 71.3m) |
| D: 0.65 (Book Value of Equity 26.1m / Total Liabilities 40.1m) |
| Altman-Z'' Score: -0.27 = B |
Beneish M -3.29
| DSRI: 0.82 (Receivables 10.4m/11.3m, Revenue 41.3m/36.8m) |
| GMI: 0.99 (GM 84.49% / 83.31%) |
| AQI: 0.94 (AQ_t 0.43 / AQ_t-1 0.46) |
| SGI: 1.12 (Revenue 41.3m / 36.8m) |
| TATA: -0.15 (NI -3.33m - CFO 6.83m) / TA 65.9m) |
| Beneish M-Score: -3.29 (Cap -4..+1) = AA |
What is the price of CPIX shares?
Over the past week, the price has changed by -12.56%, over one month by -5.90%, over three months by +16.06% and over the past year by +62.29%.
Is CPIX a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CPIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.5 | 121.9% |
| Analysts Target Price | 8.5 | 121.9% |
| ValueRay Target Price | 3.6 | -7.3% |
CPIX Fundamental Data Overview January 28, 2026
P/B = 2.1473
Revenue TTM = 41.3m USD
EBIT TTM = -2.77m USD
EBITDA TTM = 2.68m USD
Long Term Debt = 5.24m USD (from longTermDebt, last quarter)
Short Term Debt = 401.4k USD (from shortTermDebt, last quarter)
Debt = 10.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.96m USD (from netDebt column, last quarter)
Enterprise Value = 51.1m USD (56.1m + Debt 10.2m - CCE 15.2m)
Interest Coverage Ratio = -4.57 (Ebit TTM -2.77m / Interest Expense TTM 606.3k)
EV/FCF = 7.62x (Enterprise Value 51.1m / FCF TTM 6.71m)
FCF Yield = 13.12% (FCF TTM 6.71m / Enterprise Value 51.1m)
FCF Margin = 16.25% (FCF TTM 6.71m / Revenue TTM 41.3m)
Net Margin = -8.06% (Net Income TTM -3.33m / Revenue TTM 41.3m)
Gross Margin = 84.49% ((Revenue TTM 41.3m - Cost of Revenue TTM 6.40m) / Revenue TTM)
Gross Margin QoQ = 88.08% (prev 81.44%)
Tobins Q-Ratio = 0.78 (Enterprise Value 51.1m / Total Assets 65.9m)
Interest Expense / Debt = 1.07% (Interest Expense 109.7k / Debt 10.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -2.19m (EBIT -2.77m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.23 (Total Current Assets 29.9m / Total Current Liabilities 24.3m)
Debt / Equity = 0.39 (Debt 10.2m / totalStockholderEquity, last quarter 26.1m)
Debt / EBITDA = -1.85 (Net Debt -4.96m / EBITDA 2.68m)
Debt / FCF = -0.74 (Net Debt -4.96m / FCF TTM 6.71m)
Total Stockholder Equity = 26.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.67% (Net Income -3.33m / Total Assets 65.9m)
RoE = -12.60% (Net Income TTM -3.33m / Total Stockholder Equity 26.4m)
RoCE = -8.76% (EBIT -2.77m / Capital Employed (Equity 26.4m + L.T.Debt 5.24m))
RoIC = -6.41% (negative operating profit) (NOPAT -2.19m / Invested Capital 34.2m)
WACC = 7.91% (E(56.1m)/V(66.3m) * Re(9.20%) + D(10.2m)/V(66.3m) * Rd(1.07%) * (1-Tc(0.21)))
Discount Rate = 9.20% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 2.75%
[DCF Debug] Terminal Value 77.82% ; FCFF base≈6.71m ; Y1≈6.44m ; Y5≈6.29m
Fair Price DCF = 7.91 (EV 113.4m - Net Debt -4.96m = Equity 118.4m / Shares 15.0m; r=7.91% [WACC]; 5y FCF grow -5.30% → 2.90% )
EPS Correlation: -6.59 | EPS CAGR: 6.08% | SUE: 0.0 | # QB: 0
Revenue Correlation: -2.35 | Revenue CAGR: -0.09% | SUE: 2.75 | # QB: 2